Mandeg, Jennie L.

HRN: 23-14-15  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/01/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
06/01/2023
06/08/2023
IV
900 Mg
Every 8 Hours
Breast Abscess
Waiting Final Action 
06/02/2023
CEFUROXIME 1.5GM (VIAL)
06/02/2023
06/09/2023
IV
1.5 G
Q8
S/p Primary LTCS
Waiting Final Action 
06/02/2023
METRONIDAZOLE 125MG/5ML, 60ML (BOT)
06/02/2023
06/09/2023
IV
500 Mg
Q8
S/P Primary LTCS
Waiting Final Action 
06/02/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
06/02/2023
06/09/2023
IV
500 Mg
Q8h
S/P 1 LTCS
Waiting Final Action 
06/05/2023
CEFUROXIME 500MG (TAB)
06/05/2023
06/12/2023
ORAL
500mg
BID
S/P Cesarean Section; Breast Abscess
Waiting Final Action 
06/05/2023
CLINDAMYCIN 300MG (CAP)
06/05/2023
06/12/2023
ORAL
300mg
TID
S/P Cesarean Section; Breast Abscess
Waiting Final Action 
06/05/2023
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
06/05/2023
06/11/2023
IVTT
1.5g
Q6H
Breast Abscess
Waiting Final Action 
06/05/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
06/05/2023
06/11/2023
IVTT
600mg
Q8H
Breast Abscess
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: